Consensus AbbVie Inc.

Stocks

ABBV

US00287Y1091

Pharmaceuticals

Real-time Estimate Cboe BZX 10:33:27 2026-10-21 EDT			5-day change	1st Jan Change
285.34 ^USD	-1.29%		+0.83%	+25.09%

10:06am	Abbvie Canada Reaches Agreement with the Pan-Canadian Pharmaceutical Alliance for Elahere® in Platinum-Resistant Ovarian Cancer	CI
10:05am	Allergan Aesthetics Presents New and Long-Term Evidence Across Harmonyca?, Juvéderm®, Skinvive? and Botox® Cosmetic At Amwc Dubai	CI

Evolution of the Average Target: AbbVie Inc.

Evolution of the Target Price: AbbVie Inc.

Changes in Analyst Recommendations: AbbVie Inc.

b3ffb32d24a3ed8fcfc81.9HQnKExJzPlyhoD037Hy4fMhTeecSn7HgNNk4tRd9Gc.pA5XW3ol9KEBsMegqdjfjoJlPtL1AU2j1aY10axtuAKmIEARDwemiz_3uA~68b615f978b163d25178051632649b66

Analysts' recommendations: AbbVie Inc.

05:51am	BofA: UCB's Bimzelx Sets 'Very High' Bar Ahead of Q4 Competitor Data in Hidradenitis Suppurativa	MT
05:23am	Barclays Adjusts Price Target on AbbVie to $325 From $300	MT
10-20	Spyre's Ulcerative Colitis Combo Approach Gains Support From AbbVie Data, UBS Says	MT
10-20	Global markets live: Google, Apple, Amazon, 3M, Waymo…
10-13	AbbVie Poised for Q3 Top-Line Beat Driven by Rinvoq, Skyrizi, and Vraylar Therapies, RBC Says	MT
10-09	UBS Adjusts Price Target on AbbVie to $275 From $260, Maintains Neutral Rating	MT
10-09	BofA Securities Adjusts AbbVie Price Target to $305 From $289	MT
10-08	Cantor Fitzgerald Adjusts Price Target on AbbVie to $290 From $285	MT
10-08	JPMorgan Adjusts Price Target on AbbVie to $300 From $285	MT
10-07	Morgan Stanley Adjusts Price Target on AbbVie to $310 From $296	MT
10-06	AbbVie's Epkinly Could Be Preferred Frontline DLBCL Agent, UBS Says	MT
10-06	Scotiabank Adjusts Price Target on AbbVie to $320 From $280, Maintains Sector Outperform Rating	MT
09-29	AbbVie Shows Pipeline-Driven Upside Beyond Core Immunology Franchise, BofA Says	MT
09-29	BofA Securities Adjusts AbbVie Price Target to $289 From $282, Maintains Buy Rating	MT
09-24	Oruka Therapeutics' Psoriasis Treatment Maintains 'Competitive Profile' After Positive Clinical Data, UBS Says	MT
09-10	HSBC Adjusts Price Target on AbbVie to $315 From $300, Keeps Buy Rating	MT
09-08	BofA Securities Adjusts Price Target on AbbVie to $282 From $276	MT
08-20	Piper Sandler Adjusts Price Target on AbbVie to $303 From $298, Maintains Overweight Rating	MT
08-17	Wells Fargo Adjusts Price Target on AbbVie to $300 From $295, Keeps Overweight Rating	MT
08-13	Wolfe Upgrades AbbVie to Outperform From Peer Perform, Price Target is $300	MT
08-11	BNP Paribas Adjusts Price Target on AbbVie to $247 From $218, Maintains Neutral Rating	MT
08-05	Argus Lifts AbbVie Price Target to $270 From $250	MT
08-05	Leerink Partners Adjusts Price Target on AbbVie to $279 From $245	MT
08-04	Guggenheim Adjusts Price Target on AbbVie to $288 From $261, Maintains Buy Rating	MT
08-04	Rothschild & Co Redburn Adjusts Price Target on AbbVie to $285 From $284, Maintains Buy Rating	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ABBVIE INC.					-2.24%
	ELI LILLY AND COMPANY					+3.71%
	JOHNSON & JOHNSON					+7.73%
	ROCHE HOLDING AG					-1.52%
	MERCK & CO., INC.					+6.92%
	NOVARTIS AG					-2.21%
	ASTRAZENECA PLC					+24.46%
	AMGEN INC.					-10.02%
	GILEAD SCIENCES, INC.					+2.33%
	NOVO NORDISK A/S					+14.12%
	Average					+4.33%
	Weighted average by Cap.					+3.87%